Therapy Areas: Hereditary Disorders
Pulmatrix Releases Results from Phase 1 Study of PUR0200 in COPD Patients
18 June 2018 - - Lexington, Massachusetts-based pulmonary disease inhaled therapeutics developer Pulmatrix, Inc. (NASDAQ: PULM) has published data from a dose-ranging Phase 1 clinical study of PUR0200 in chronic obstructive pulmonary disease (COPD) patients, the company said.
PUR0200 combines tiotropium bromide, the active component in the drug Spiriva, with Pulmatrix's innovative iSPERSE drug delivery platform.
iSPERSE utilises salt based excipients and spray-drying to create particles for inhalation that are intended to improve the delivery of drugs to the lungs compared to lactose-blend dry powders.
In the published study, moderate-to-severe COPD patients were administered one of three PUR0200 doses (3mg, 6mg or 9mg tiotropium bromide), Spiriva HandiHaler (18mg tiotropium bromide) or placebo in a cross-over study design.
PUR0200 treatment at all doses resulted in a statistically significant increase in forced expiratory volume in one second compared to placebo and caused similar bronchodilation compared to Spiriva HandiHaler.
The lowest PUR0200 dose achieved a similar clinical effect to Spiriva HandiHaler at a dose that was 83% lower and resulted in >30% less plasma drug exposure.
Pulmatrix is developing innovative inhaled therapies to address serious pulmonary disease.
The company's product pipeline is focused on advancing treatments for rare diseases, including severe asthma, cystic fibrosis, COPD.
Pulmatrix's product candidates are based on iSPERSE, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.


Related Headlines